



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** March 26, 2010

**To:** Primary Clinical Research Associates

**From:** Sara Braun  
Research Protocol Specialist III

**Re:** N057K, Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

The Research Blood Requisition Form has been updated to reflect Biospecimen Accessioning Processing rather than Mayo Medical Laboratory.

If you have any questions, please feel free to contact me.

Enclosure